NCT01399606View on ClinicalTrials.gov

Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)

PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

September 30, 2016

Conditions
NarcolepsyCataplexy
Interventions
DRUG

BF2.649

5,10,20,or 40 mg per day, in a once daily scheme

Trial Locations (1)

34000

CHU Montpellier, Montpellier

Sponsors

Lead Sponsor

Bioprojet
All Listed Sponsors
lead

Bioprojet

OTHER

NCT01399606 - Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant) | Biotech Hunter | Biotech Hunter